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We evaluated the eﬃcacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identi-
ﬁed prognostic factors in Japanese patients with cancer of unknown primary site (CUP).  Twenty-eight 
consecutive patients seen at a single institute were reviewed retrospectively.  Sixteen patients were 
treated with TXT 80mg/m2,  followed by CDDP 75mg/m2.  The overall response rate to CDDP/TXT 
treatment was 62.5ｵ,  with a median survival time (MST) of 22.7 months.  Common adverse reactions 
were myelosuppression and hyponatremia.  The MST of all 28 patients with CUP was 8.3 months,  and 
the 1-year overall survival rate was 45.6ｵ.  Univariate analysis identiﬁed 5 prognostic 
factors:performance status,  liver involvement,  bone involvement,  pleural involvement,  and lymph 
node involvement.  In conclusion,  CDDP/TXT chemotherapy is eﬀective with tolerable toxicity in 
patients with CUP.  Japanese patients with CUP might be chemosensitive and may survive longer.
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ancer of unknown primary site (CUP) is deﬁned 
as the presence of metastatic cancer documented 
in the absence of an identiﬁable primary tumor site.  
These tumors are not rare; they represent 3-5ｵ of 
all malignancies diagnosed in oncology practice [1,  
2].  CUP occurs in a heterogeneous group of patients,  
and subgroups with treatment-responsive diseases 
exist that may achieve long-term,  disease-free sur-
vival [1].  Generally,  however,  the prognosis of CUP 
is poor,  with median survival times of 6-12 months,  
and the beneﬁts of chemotherapy compared with best 
supportive care remain unclear [3].
　 Chemotherapy for patients with CUP is improving,  
but no chemotherapy regimen has been established as 
a standard ﬁrst-line therapy for these patients [2].  
Recent clinical reports have shown that cisplatin 
(CDDP)-containing regimens have good response rates 
of 32-55ｵ in patients with CUP and are relatively 
well-tolerated [3,  4].  Docetaxel (TXT) has deﬁnite 
antitumor activity in various solid tumors and seems to 
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be a good candidate for inclusion in a chemotherapy 
regimen for patients with CUP [5].  A CDDP plus 
TXT phase II study revealed a 26ｵ response rate 
with 42ｵ 1-year survival [6].
　 This paper presents a retrospective analysis of 28 
consecutive Japanese patients with CUP to clarify the 
disease course and prognostic factors.  We also report 
an excellent response rate and survival of Japanese 
patients with CUP who were treated using a combina-
tion regimen of CDDP/TXT.
Patients and Methods
　 Patients. Twenty-eight consecutive patients 
referred to the Division of Medical Oncology and 
Hematology at the Cancer Institute Hospital between 
April 1,  2000 and September 30,  2004 were reviewed 
retrospectively.  Patients referred with a presumed 
diagnosis of CUP were identiﬁed and registered in the 
database at the time of their initial clinical evaluation.  
All patients diagnosed with CUP during this period 
were registered; however,  2 female patients with 
adenocarcinoma involving only the axillary lymph 
nodes were treated for occult breast cancer and were 
excluded from this analysis.  The medical records of 
the patients were reviewed for the results of diagnos-
tic studies and pathologic and cytologic diagnosis 
before referral,  the results of subsequent radio-
graphic evaluations,  pathology review,  involved dis-
ease sites,  treatment,  and survival.
　 Clinical evaluation. All patients with CUP 
underwent a basic evaluation consisting of a complete 
medical history,  a physical examination (including 
careful palpation of the thyroid,  breasts,  lymph nodes,  
and prostate),  general laboratory studies,  chest radi-
ography,  and computed tomography from the neck to 
pelvis.  If possible,  gastrointestinal endoscopy,  nose 
and pharyngeal endoscopy,  and bronchoscopy were 
conducted.  Positron emission tomography (PET) was 
performed in some patients when all other tests were 
inconclusive.  In some cases,  an extensive immunohis-
tochemical study was carried out with the biopsied 
specimen to minimize the possibility of a misdiagnosis 
of other malignancies such as non-Hodgkinʼs lymphoma,  
extragonadal germ cell tumor,  malignant melanoma,  
or undiﬀerentiated sarcoma [2].  The most commonly 
used markers were the leukocyte common antigen,  
cytokeratins,  neuron-speciﬁc enolase or chromogra-
nin,  S-100 protein,  vimentin,  thyroid transcription 
factor-1 (TTF-1),  estrogen receptors,  HMB45,  and 
prostate-speciﬁc antigen (PSA).  The blood concentra-
tions of CA19-9,  CA15-3,  CA125,  and carcinoem-
bryonic antigen (CEA) were assessed in most cases.
　 Decision-making in the ʻcancer board meet-
ingʼ. Determining whether the primary site is 
unknown or whether it will be possible to detect with 
further evaluation is diﬃcult.  In the present study,  
members of the cancer board,  including medical 
oncologists,  hematologists,  surgeons,  pathologists,  
and radiation oncologists,  evaluated the diagnosis and 
treatment strategies for the patients with CUP.
　 Treatment schedule for CDDP/TXT ther-
apy. Eligible patients with CUP were treated with 
CDDP/TXT combination chemotherapy.  All patients 
gave written informed consent.  TXT 80mg/m2 in 
300mL of normal saline was administered over 2h,  
followed by CDDP 75mg/m2,  which was administered 
via a 120-min intravenous infusion.  Premedication 
included intravenous administration of 4mg of dexam-
ethasone 24h before treatment,  30min before starting 
the docetaxel infusion,  and 24h after the infusion.  A 
single 3-mg intravenous dose of granisetron was given 
to all patients as an antiemetic.  Concurrent radio-
therapy for symptom control in the absence of disease 
progression was allowed,  but the drugs were held for 
at least 2 weeks after irradiation.  Chemotherapy 
cycles were repeated every 3 weeks.  Doses were 
modiﬁed for some patients mainly due to hematological 
toxicity.
　 Assessment of response and toxicity.
Responses were deﬁned according to the World Health 
Organization criteria [7].  Brieﬂy,  complete response 
(CR) was deﬁned as the entire disappearance of all 
assessable lesions and signs of disease for at least 4 
weeks.  Partial response (PR) was deﬁned as a reduc-
tion of 50ｵ or more in the sum of the products of the 
perpendicular dimensions of measurable lesions and the 
appearance of no new lesion for at least 4 weeks.  No 
change (NC) was deﬁned as a decrease of less than 
50ｵ or an increase of less than 25ｵ in the 2 great-
est dimensions of measurable lesions and the appear-
ance of no new lesions.  Progressive disease (PD) was 
deﬁned as any evidence of disease progression of 25ｵ 
or more,  or the appearance of a new lesion.  
Chemotherapy-related adverse events were recorded 
according to the National Cancer Instituteʼs Common 
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Terminology Criteria,  version 3.0 [8].
　 Statistical methods. Survival was calculated 
from the ﬁrst day of pathologically or cytologically 
diagnosed malignancy.  Survival following CDDP/
TXT therapy was calculated from the ﬁrst day of 
treatment.  Survival curves were estimated using the 
Kaplan-Meier method [9] and compared using the 
Cox-Mantel log-rank test [10].  StatView 5.0 (SAS 
Institute,  Cary,  NC,  USA) was used for the statisti-
cal analyses.
Results
　 General patient characteristics. The charac-
teristics of our 28 patients (19 men and 9 women) are 
listed in Tables 1 and 2.  One female patient was 
excluded from the survival analysis because she was 
postoperatively diagnosed with ovarian cancer.  The 
median age at diagnosis was 58.5 years (range 32-76 
years).  Performance status according to the Eastern 
Cooperative Oncology Group (ECOG) [11] was 0-1 
in 17 patients (60.7ｵ).  The sites of metastasis docu-
mented pathologically,  cytologically,  or radiographi-
cally are listed in Table 3.  Lymph nodes were 
involved most frequently (64.3ｵ),  and visceral metas-
tases including bone,  lung,  or liver were also common.  
The lymph node involvement was further subclassiﬁed 
by anatomic site.  Of the 18 patients with nodal metas-
tases,  11 had retroperitoneal,  8 had supraclavicular 
or cervical,  7 had mediastinal,  4 had axillary,  and 4 
had inguinal lymph nodes.
　 The pathological diagnoses of the patients are also 
listed in Table 2.  Thirteen patients (46.4ｵ) were 
diagnosed with adenocarcinoma,  9 (32.1ｵ) with poorly 
diﬀerentiated carcinoma,  2 (7.1ｵ) with squamous cell 
carcinoma,  and 4 with unknown or other diagnoses.  
One patient was diagnosed based only on the cytology 
of ascites.  No patients with neuroendocrine carcinoma 
were included in this study.  No patients appeared to 
belong to subgroups with a favorable prognosis [1].
　 Twelve patients (42.9ｵ) had a single metastatic 
organ site,  4 (14.3ｵ) had 2,  7 (25.0ｵ) had 3,  and 5 
(17.9ｵ) had 4 or more.  Serum tumor markers at 
baseline were assessed in all 16 patients who under-
went CDDP/TXT therapy.
　 Twenty-ﬁve patients (89.3ｵ) were treated with 
chemotherapy with or without concurrent radiother-
apy for symptom control.  One patient was treated 
with radiotherapy only.  Two patients were treated 
with supportive care alone.
　 CDDP/TXT treatment. Sixteen patients who 
received the CDDP/TXT combination according to the 
protocol were assessable for response.  The patient 
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Table 1　 Characteristics of 28 CUP patients
Characteristic No. of Patients
Sex
　　Female 9 　
　　Male 19 　
Age, years
　　 0-40 1 　
　　41-50 6 　
　　51-60 8 　
　　61-70 10 　
　　71-80 3 　
　　Median 58.5
　　Range 32-76
Performance status
　　 0-1 17 　
　　 2-3 11 　
Table 2　 Sites of tumor involvement and histologic diagnoses in 
28 patients with CUP
Site of involvement No. of patients
Lymph nodes 18
Bone 10
Lung 7
Liver 6
Pleura/pleural space 4
Peritoneum 4
Skin 3
Adrenal 2
Others 9
Histologic Diagnosis No. of patients
Adenocarcinoma 13
　　Poorly diﬀerentiated 4
　　Papillary 1
　　No descriptor/other 8
Poorly diﬀerentiated carcinoma 9
Squamous cell carcinoma 2
Unknown/other 4
No. of involved organ sites No. of patients
　　1 12
　　2 4
　　3 7
　　4 or more 5
characteristics were similar to those of all 28 
patients (Table 3): 10 men and 6 women,  median age 
62.5 years (range 41-76 years).  However,  perfor-
mance status (PS) and the number of metastatic sites 
were lower,  with PS 0-1 in 12 patients and single-site 
involvement in 9.  In 8 patients (50ｵ),  more than 2 
tumor markers had increased at diagnosis.  The 
median duration from the day of the pathological 
diagnosis of metastatic carcinoma to the ﬁrst day of 
CDDP/TXT therapy was 43 days (range 0-154 days).  
A total of 44 cycles of therapy was given,  and the 
patients underwent a median of 3 treatment cycles 
(range 1-6 cycles).  Doses were modiﬁed mainly 
because of hematological toxicity; 4 patients had a 
20ｵ dose reduction.
　 The overall response rate was 62.5ｵ (95ｵ CI 
8.6-81.5ｵ),  with CR in one patient and PR in nine 
patients.  Six of 10 patients with adenocarcinoma 
responded,  and all 4 patients with poorly diﬀerenti-
ated carcinoma responded.  Tumor markers decreased 
in most responding patients.  Fig.  1 shows the survival 
curve for these patients.  The median follow-up was 
20.4 months (range 1.7-60.2 months),  the median dis-
ease-free survival (DFS) was 8.7 months,  the 1-year 
overall survival (OS) rate was 68.8ｵ (95ｵ CI 40.6-
91.5ｵ),  and the median OS was 22.7 months.  The 
median hospitalization stay of the 16 patients treated 
with CDDP/TXT therapy was 65.5 days (range 
26-162 days).
　 Toxicity data are listed in Table 4.  Grade 3-4 
neutropenia was frequent (14 patients,  87.5ｵ).  One 
patient who had multiple lung,  liver,  and bone metas-
tases died of bacterial pneumonia due to neutropenia.  
Hyponatremia occurred in 14 patients (87.5ｵ) and was 
grade 3-4 in 3 patients; however,  all patients were 
able to continue the treatment.  The hyponatremia was 
caused by a loss of sodium due to renal tubule damage 
caused by cisplatin or the syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH).  Grade 3 
allergic reactions due to docetaxel occurred in 2 
patients during the ﬁrst course.  These 2 patients 
were given hydrocortisone and treated with cisplatin-
only beginning with the next course.  Other recorded 
toxicities were mild to moderate.
　 Prognostic factors for survival in the 28 
patients with CUP. Fig.  2 shows the survival 
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Table 3　 Characteristics of 16 patients treated with the CDDP/
TXT regimen
Characteristic No. of Patients
Sex
　　Female 6 　
　　Male 10 　
Age,  years
　　Median 62.5
　　Range 41-76
PS
　　0-1 12 　
　　2-3 4 　
Histology
　　Adonocarcinoma 10 　
　　　　Poorly diﬀerentiated 2 　
　　　　Papillary 1 　
　　　　No descriptor/other 7 　
　　Poorly diﬀerentiated Carcinoma 4 　
　　Squamous cell carcinoma 0 　
　　Unknown/other 2 　
Metastatic sites at presentation
　　Lymph nodes 10 　
　　Bone 6 　
　　Lung 2 　
　　Liver 1 　
　　Pleura/pleural space 1 　
　　Peritoneum 2 　
　　Skin 1 　
　　Adrenal 1 　
　　Others 4 　
No. of involved organ sites
　　Single site 9 　
　　Multiple (ｧ2) sites 7 　
No. of courses given
　　Median 3 　
　　Range 1-6
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Fig. 1　 Kaplan-Meier survival curve for the CUP patients treated 
with CDDP/TXT chemotherapy (n＝16).
curve for the 28 patients with CUP calculated from 
the day of diagnosis.  The 1-year OS rate for all 28 
patients was 45.6ｵ (95ｵ CI 26.8-64.4ｵ),  and the 
median survival was 8.3 months.
　 Table 5 lists the median survival of the CUP 
patient subgroups according to various factors.  The 
univariate analysis revealed that 4 factors were 
deleterious: performance status 2-4,  liver involve-
ment,  bone involvement,  and pleural involvement.  The 
advantageous clinical feature was lymph node involve-
ment.
Discussion
　 In this study,  we obtained an excellent response 
rate and survival with CDDP/TXT therapy for 
patients with CUP.  An overall response rate of 
62.5ｵ was seen in patients with CUP who were given 
the CDDP/TXT combination once every 3 weeks.  
The median disease-free survival was 8.7 months.  The 
1-year OS was 68.8ｵ,  and the median OS was 22.7 
months.  The response rate and survival were superior 
to those obtained in the reported phase II trials of 
platinum plus taxane-based chemotherapy [2,  5,  6,  
12].  Greco et al.  reported a prospective phase II 
study of the CDDP/TXT regimen with a response 
rate of 22ｵ and a 1-year survival of 40ｵ [6].  The 
patient characteristics and dose intensity were similar 
to those in our study,  although they had fewer 
patients with a single metastasis.
　 Yakushiji et al.  have reported that 35 Japanese 
patients received a median of four cycles of CDDP 
and TXT,  and had a response rate of 57.1ｵ.  The 
median survival time was 13.2 months [13].  These 
results in Japanese patients together with ours in the 
present study seem to be better than those reported 
from other countries.  Although the prognostic factors 
in our reports are similar to those for other countries,  
Japanese patients with CUP might be chemosensitive 
and thus survive longer.
　 The treatment-related toxicity of the CDDP/TXT 
regimen mainly involved myelosuppression; in particu-
lar,  grade 3-4 neutropenia was severe.  Non-prophy-
lactic G-CSF seemed to be the cause of this severity.  
One patient died of bacterial pneumonia due to neutro-
penia on day 12 of the ﬁrst course.  This patient was 
a 62-year-old man with PS 3.  He had multiple metas-
tases to lung,  liver,  and bone.  He was therefore at 
high risk of pneumonia and had a very poor prognosis.  
Although hyponatremia occurred in 87.5ｵ of our 
patients,  it has not been reported in other studies that 
treated patients with CUP using platinum-containing 
regimens.  Greco et al.  have reported the toxicities of 
CDDP/TXT therapy to consist primarily of gastroin-
testinal events,  with myelosuppression being moderate 
[6].  Based on urinalysis and the serum osmolarity,  
SIADH was the main cause of hyponatremia in the 
present study (data not shown).  Since 1990,  many 
Japanese researchers have reported SIADH following 
platinum administration for solid tumors [14,  15].  
Collectively,  Japanese patients seem to be more sensi-
tive to platinum in terms of developing SIADH.  Other 
recorded toxicities are mild to moderate.  Overall,  the 
regimen is generally tolerated in the majority of 
patients.
289Review of 28 CUP Cases in JapanOctober 2010
Table 4　 Toxicity of CDDP/TXT therapy as worst grade per 
patient (n＝16)
Toxicity
No. of patients (%)
Grade 1 Grade 2 Grade 3 Grade 4
Anemia  6 (37.5) 6 (37.5) 1 　　 0 　　
Thrombocytopenia  4 (25.0) 1 　　 0 　　 1 　　
Leukocytopenia  0 　　 5 (31.3) 7 (43.8) 3 (18.8)
Granulocytopenia  0 　　 1 　　 3 (18.8) 11 (68.8)
Diarrhea  2 (12.5) 0 　　 0 　　 0 　　
Nausea  3 (18.8) 5 (31.3) 4 (25.0) 0 　　
Hyponatremia 11 (68.8) 0 　　 3 (18.8) 0 　　
High serum bilirubin  2 (12.5) 0 　　 1 　　 0 　　
High serum creatinine  7 (43.8) 0 　　 0 　　 0 　　
Allergic reaction  0 　　 0 　　 2 (12.5) 0 　　
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Fig. 2　 Kaplan-Meier survival curve of all 28 CUP patients.
　 Clinical subsets of patients who are sensitive to 
platinum-containing treatment have been identiﬁed in 
the last 2 decades [2].  In this study,  one patient 
almost ﬁt into a favorable subset.  She was a 73-year-
old woman with peritoneal adenocarcinoma,  but no 
papillary serous carcinoma,  so she did not completely 
conform to a favorable subset.  She was given three 
courses of CDDP/TXT,  attained good PR,  and was 
still alive at the 23.6-month follow-up.  Therefore,  
although no patients completely matched the subgroups 
with a favorable prognosis,  the CDDP/TXT regimen 
in this study was found to be very beneﬁcial.
　 We also analyzed the course and prognostic factors 
of the patients with CUP.  Univariate analysis identi-
fied 4 factors predicting a poor prognosis:  
performance status 2-4,  liver involvement,  bone 
involvement,  and pleural involvement.  The one favor-
able prognostic factor was lymph node involvement.  
Abbruzzese et al.  examined prognostic factors in 657 
consecutive patients and found that male sex,  
increased numbers of involved organ sites,  adenocar-
cinoma histology,  and hepatic involvement were nega-
tive prognostic factors in a multivariate analysis [16].  
They also reported that lymph node involvement,  
290 Acta Med.  Okayama　Vol.  64,  No.  5Nishimori et al.
Table 5　 Median survival duration of deﬁned patient populations with CUP
Variable No. of Patients Median survival(days) p-value
Sex
　　Female  9 712 0.2599
　　Male 19 186
No. of organ sites
　　1 12 709 0.1180
　　2-6 16 108
Performance status
　　0-1 17 673 0.0413
　　2-3 11  79
Involved organ sites
　　Lymph nodes　　　　 ＋ 18 673 0.0310
　　　　　　　　　　－ 10 148
　　Liver　　　　　　　　 ＋  6  50 0.0002
　　　　　　　　　　－ 22 673
　　Bone　　　　　　　　＋ 10 108 0.0380
　　　　　　　　　　－ 18 673
　　Lung　　　　　　　　 ＋  7  67 0.0642
　　　　　　　　　　－ 21 604
　　Pleura/pleural space　＋  4  31 0.0040
　　　　　　　　　　－ 24 604
　　Brain　　　　　　　　 ＋  1 108 0.3704
　　　　　　　　　　－ 27 306
　　Peritoneum　　　　　 ＋  4  67 0.1458
　　　　　　　　　　－ 24 306
　　Adrenal　　　　　　　 ＋  2  33 0.6633
　　　　　　　　　　－ 26 249
　　Skin　　　　　　　　 ＋  3  51 0.1820
　　　　　　　　　　－ 25 306
Therapy
　　CDDP/TXT 16 681 ＜0.0001
　　Other 12  73
Histology
　　Adenocarcinoma 13 673
　　Poorly diﬀerentiated carcinoma  9 306
　　Squamous cell carcinoma  2  33
　　Unknown or others  4  67
peritoneal involvement,  and neuroendocrine histology 
are favorable prognostic factors [16].  Our results 
conﬁrm the reported analyses; i.e.,  visceral metasta-
sis,  multiple metastatic sites,  and poor performance 
status may predict shorter survival.
　 Recently,  a new combination of chemotherapy has 
been reported that includes gemcitabine,  etoposide,  
or irinotecan combined with platinum plus taxane;  
these studies have shown similar response and survival 
rates [17,  18].  New agents such as vascular 
endothelial growth factor (VEGF) inhibitors and epi-
dermal growth factor receptor (EGFR) inhibitors are 
being tested to improve the prognosis of CUP.  
Hainsworth et al.  have reported that bevacizumab plus 
erlotinib therapy has a response rate of 10ｵ,  leading 
to stable disease in 61ｵ,  a median OS of 7.4 months,  
and a 1-year OS of 33ｵ [19].  Therapeutic trials 
involving platinum and taxane plus VEGF or EGFR 
inhibitors should be conducted to improve the survival 
of patients with CUP.
　 In conclusion,  although this was a retrospective 
study,  we observed an excellent response rate and 
survival with CDDP/TXT chemotherapy in Japanese 
patients with CUP,  despite their being in unfavorable 
subgroups.  Our results show that bone,  liver,  and 
pleural metastasis,  and poor performance status may 
predict a shorter survival.
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